Reviewing Unity Biotechnology (NASDAQ:UBX) and Corbus Pharmaceuticals (NASDAQ:CRBP)

Unity Biotechnology (NASDAQ:UBX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Volatility & Risk

Unity Biotechnology has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500.

Earnings and Valuation

This table compares Unity Biotechnology and Corbus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240,000.00	67.48	-$39.86 million	($1.53)	-0.63
Corbus Pharmaceuticals	N/A	N/A	-$44.60 million	($3.66)	-1.37

Unity Biotechnology has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Unity Biotechnology and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Corbus Pharmaceuticals	N/A	-42.28%	-32.92%

Analyst Ratings

This is a summary of recent recommendations for Unity Biotechnology and Corbus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0	0	3	0	3.00
Corbus Pharmaceuticals	0	0	9	1	3.10

Unity Biotechnology presently has a consensus target price of $5.33, suggesting a potential upside of 455.50%. Corbus Pharmaceuticals has a consensus target price of $59.13, suggesting a potential upside of 1,075.45%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Unity Biotechnology.

Institutional and Insider Ownership

29.5% of Unity Biotechnology shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 5.8% of Unity Biotechnology shares are owned by insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Unity Biotechnology on 8 of the 13 factors compared between the two stocks.

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.